APA (7. basım) Alıntı

Priestman, D., Welford, R., Platt, F., Muhlemann, A., Garzotti, M., Deymier, C., . . . Probst, M. (2017). Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: Preclinical evidence. Elsevier.

Chicago Style (17. basım) Atıf

Priestman, D., et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence. Elsevier, 2017.

MLA (9th ed.) Atıf

Priestman, D., et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence. Elsevier, 2017.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..